Inside informationEnglish
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Nicox SA
- Filed
- 24/02/2026, 07:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 116241_20260224